Survival estimates of prognostic factors in 11q23/MLL-rearranged AML, including subgroups based on translocation partners
| . | 5-year pEFS . | 5-year pCIR . | 5-year pOS . | |||
|---|---|---|---|---|---|---|
| Mean percentage (SE) . | P* (log rank) . | Mean percentage (SE) . | P* (Gray test) . | Mean percentage (SE) . | P* (log rank) . | |
| MLL rearrangement | ||||||
| All | 44 (2) | 35 (2) | 56 (2) | |||
| t(1;11)(q21;q23) | 92 (5) | < .001 | 4 (4) | < .001 | 100 (0) | < .001 |
| t(9;11)(p22;q23) | 50 (3) | 29 (3) | 63 (3) | |||
| t(11;19)(q23;p13) | 49 (9) | 24 (8) | 49 (10) | |||
| t(11;19)(q23;p13.1) | 46 (9) | 42 (9) | 61 (9) | |||
| t(11;19)(q23;p13.3) | 46 (10) | 21 (9) | 47 (11) | |||
| t(11;17)(q23;q21) | 42 (14) | 41 (15) | 67 (14) | |||
| t(10;11)(p12;q23) | 31 (5) | 52 (5) | 45 (5) | |||
| t(4;11)(q21;q23) | 29 (13) | 56 (16) | 27 (13) | |||
| t(10;11)(p11.2;q23) | 17 (11) | 50 (16) | 27 (13) | |||
| t(6;11)(q27;q23) | 11 (5) | 54 (9) | 22 (7) | |||
| Other | 39 (4) | 40 (5) | 54 (5) | |||
| Additional cytogenetic aberrations | ||||||
| No | 48 (3) | .01 | 31 (3) | .03 | 61 (3) | .002 |
| Yes | 39 (3) | 39 (3) | 48 (3) | |||
| WBC | ||||||
| Less than 20 × 109/L, n (%) | 48 (3) | .004 | 45 (3) | .6 | 59 (3) | .004 |
| 20 to less than 100 × 109/L, n (%) | 43 (4) | 42 (4) | 57 (4) | |||
| 100 × 109/L or more, n (%) | 36 (4) | 46 (4) | 47 (4) | |||
| Age | ||||||
| Less than 10 y | 46 (2) | .006 | 43 (3) | .048 | 60 (2) | .001 |
| 10 y or more | 34 (4) | 51 (4) | 42 (4) | |||
| . | 5-year pEFS . | 5-year pCIR . | 5-year pOS . | |||
|---|---|---|---|---|---|---|
| Mean percentage (SE) . | P* (log rank) . | Mean percentage (SE) . | P* (Gray test) . | Mean percentage (SE) . | P* (log rank) . | |
| MLL rearrangement | ||||||
| All | 44 (2) | 35 (2) | 56 (2) | |||
| t(1;11)(q21;q23) | 92 (5) | < .001 | 4 (4) | < .001 | 100 (0) | < .001 |
| t(9;11)(p22;q23) | 50 (3) | 29 (3) | 63 (3) | |||
| t(11;19)(q23;p13) | 49 (9) | 24 (8) | 49 (10) | |||
| t(11;19)(q23;p13.1) | 46 (9) | 42 (9) | 61 (9) | |||
| t(11;19)(q23;p13.3) | 46 (10) | 21 (9) | 47 (11) | |||
| t(11;17)(q23;q21) | 42 (14) | 41 (15) | 67 (14) | |||
| t(10;11)(p12;q23) | 31 (5) | 52 (5) | 45 (5) | |||
| t(4;11)(q21;q23) | 29 (13) | 56 (16) | 27 (13) | |||
| t(10;11)(p11.2;q23) | 17 (11) | 50 (16) | 27 (13) | |||
| t(6;11)(q27;q23) | 11 (5) | 54 (9) | 22 (7) | |||
| Other | 39 (4) | 40 (5) | 54 (5) | |||
| Additional cytogenetic aberrations | ||||||
| No | 48 (3) | .01 | 31 (3) | .03 | 61 (3) | .002 |
| Yes | 39 (3) | 39 (3) | 48 (3) | |||
| WBC | ||||||
| Less than 20 × 109/L, n (%) | 48 (3) | .004 | 45 (3) | .6 | 59 (3) | .004 |
| 20 to less than 100 × 109/L, n (%) | 43 (4) | 42 (4) | 57 (4) | |||
| 100 × 109/L or more, n (%) | 36 (4) | 46 (4) | 47 (4) | |||
| Age | ||||||
| Less than 10 y | 46 (2) | .006 | 43 (3) | .048 | 60 (2) | .001 |
| 10 y or more | 34 (4) | 51 (4) | 42 (4) | |||
pEFS indicates probability of event-free survival; pCIR, probability of cumulative incidence of relapse; pOS, probability of overall survival; WBC, white blood cell count.
P values indicate whether the differences are significant between the subgroups.